Benchtop and bedside validation of a low-cost programmable cortical stimulator in a testbed for bi-directional brain-computer-interface research

• Published in: Frontiers in neuroscience Vol. 16; p. 1075971
• Main Authors: Sohn, Won Joon, Lim, Jeffrey, Wang, Po T, Pu, Haoran, Malekzadeh-Arasteh, Omid, Shaw, Susan J, Armacost, Michelle, Gong, Hui, Kellis, Spencer, Andersen, Richard A, Liu, Charles Y, Heydari, Payam, Nenadic, Zoran, Do, An H
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 12.01.2023; Frontiers Media S.A
• Subjects: Batteries; bi-directional BCI (BD-BCI); brain computer interface; Brain mapping; Brain research; brain stimulator; Cortex (somatosensory); cortical stimulator; Design; Digitization; Electrical stimuli; Electrodes; Embedded systems; Epilepsy; FDA approval; Interfaces; Medical equipment; miniaturized stimulator; neuroprosthetics; Neuroscience; Printed circuit boards; Prostheses; Sensation; Sensors; Signal processing; Spinal cord injuries; Voltage; United States > US; Texas; brain computer interface; miniaturized stimulator; cortical stimulator; brain stimulator; neuroprosthetics; bi-directional BCI (BD-BCI)
• ISSN: 1662-4548; 1662-453X; 1662-453X
• DOI: 10.3389/fnins.2022.1075971

Bi-directional brain-computer interfaces (BD-BCI) to restore movement and sensation must achieve concurrent operation of recording and decoding of motor commands from the brain and stimulating the brain with somatosensory feedback. A custom programmable direct cortical stimulator (DCS) capable of eliciting artificial sensorimotor response was integrated into an embedded BCI system to form a safe, independent, wireless, and battery powered testbed to explore BD-BCI concepts at a low cost. The BD-BCI stimulator output was tested in phantom brain tissue by assessing its ability to deliver electrical stimulation equivalent to an FDA-approved commercial electrical cortical stimulator. Subsequently, the stimulator was tested in an epilepsy patient with subcortical electrocorticographic (ECoG) implants covering the sensorimotor cortex to assess its ability to elicit equivalent responses as the FDA-approved counterpart. Additional safety features (impedance monitoring, artifact mitigation, and passive and active charge balancing mechanisms) were also implemeneted and tested in phantom brain tissue. Finally, concurrent operation with interleaved stimulation and BCI decoding was tested in a phantom brain as a proof-of-concept operation of BD-BCI system. The benchtop prototype BD-BCI stimulator's basic output features (current amplitude, pulse frequency, pulse width, train duration) were validated by demonstrating the output-equivalency to an FDA-approved commercial cortical electrical stimulator ( > 0.99). Charge-neutral stimulation was demonstrated with pulse-width modulation-based correction algorithm preventing steady state voltage deviation. Artifact mitigation achieved a 64.5% peak voltage reduction. Highly accurate impedance monitoring was achieved with > 0.99 between measured and actual impedance, which in-turn enabled accurate charge density monitoring. An online BCI decoding accuracy of 93.2% between instructional cues and decoded states was achieved while delivering interleaved stimulation. The brain stimulation mapping ECoG grids in an epilepsy patient showed that the two stimulators elicit equivalent responses. This study demonstrates clinical validation of a fully-programmable electrical stimulator, integrated into an embedded BCI system. This low-cost BD-BCI system is safe and readily applicable as a testbed for BD-BCI research. In particular, it provides an all-inclusive hardware platform that approximates the limitations in a near-future implantable BD-BCI. This successful benchtop/human validation of the programmable electrical stimulator in a BD-BCI system is a critical milestone toward fully-implantable BD-BCI systems.